Skip to main content
Premium Trial:

Request an Annual Quote

GenesisCare Takes Minority Stake in Precision Medicine Firm PreludeDx

NEW YORK — Australian cancer care provider GenesisCare said on Monday that it has taken a minority equity stake in PreludeDx, providing funds to help support the companies' recently announced breast cancer testing partnership.

Specific investment details were not disclosed.

Earlier this year, the firms signed an agreement under which PreludeDx's DCISionRT precision medicine test for women with breast cancer is being offered in Australia by GenesisCare. Patient access to the test is also being expanded in the US through GenesisCare's network of cancer centers.

The partners also agreed to work together to continue developing precision medicine tests for breast and other cancers, as well as to establish a global registry to evaluate DCISionRT's impact on treatment decision-making for women with ductal carcinoma in situ.

According to GenesisCare, the money it is providing to Laguna Hills, California-based PreludeDx through the equity investment will support the global data registry, expand the rollout of DCISionRT, and accelerate PreludeDx's development of a new early-stage breast cancer assay.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.